Effects of repeated allopurinol administration on rat cytochrome P450 activity. 2013

Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.

Allopurinol is a popular and widely-prescribed anti-hyperuricemic agent that has been implicated in drug interactions with substrates of several cytochrome P450 (CYP) enzymes. The effect of repeated allopurinol administration (20 mg/kg, once daily for 14 days) on metabolic activity of CYP was assessed in rats. This was a randomized, double-blind, two-way crossover study with a 4-week washout period between phases. The substrates used in this study were phenacetin (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19) and dextromethorphan (CYP2D6). Validated HPLC-MS/MS was used to quantify all compounds. Our study showed that allopurinol administration inhibited CYP1A2 activity, causing a significant increase in AUC (0-infinity) (P < 0.01) and t1/2 (P < 0.05) of phenacetin, and a distinct decline in CL (P < 0.01). However, there were no significant differences of another three probe drugs in plasma concentrations and the corresponding pharmacokinetic parameters between the allopurinol-treated and normal saline-treated rats. The findings in this study suggested that allopurinol could inhibit CYP1A2 but did not influence CYP2C9, CYP2C19 and CYP2D6 enzymes.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010599 Pharmacokinetics Dynamic and kinetic mechanisms of exogenous chemical DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology. ADME,ADME-Tox,ADMET,Absorption, Distribution, Metabolism, Elimination, and Toxicology,Absorption, Distribution, Metabolism, and Elimination,Drug Kinetics,Kinetics, Drug,LADMER,Liberation, Absorption, Distribution, Metabolism, Elimination, and Response
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000493 Allopurinol A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. Allohexal,Allohexan,Alloprin,Allopurin,Allorin,Allpargin,Allural,Apulonga,Apurin,Atisuril,Bleminol,Caplenal,Capurate,Cellidrin,Embarin,Foligan,Hamarin,Jenapurinol,Lopurin,Lysuron,Milurit,Milurite,Novopurol,Pan Quimica,Progout,Pureduct,Purinol,Remid,Rimapurinol,Roucol,Suspendol,Tipuric,Uribenz,Uridocid,Uripurinol,Urosin,Urtias,Xanthomax,Xanturic,Zygout,Zyloprim,Zyloric

Related Publications

Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
September 2012, Xenobiotica; the fate of foreign compounds in biological systems,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
January 2002, Anticancer research,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
July 2007, Clinical cancer research : an official journal of the American Association for Cancer Research,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
January 2012, Neuro endocrinology letters,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
January 2002, Drug metabolism and pharmacokinetics,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
October 1996, British journal of pharmacology,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
January 2014, BMC complementary and alternative medicine,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
January 2015, International journal of clinical and experimental pathology,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
April 2005, International journal of environmental research and public health,
Ren-Ai Xu, and Zhi-Sheng Xu, and Lu-Feng Hu, and Chun-Hong Zhang, and Xiao-Feng Pan, and Da-Wei Shi, and Xiao-Lan Ye, and Yun-Jie Llu, and Xiu-Hua Zhang
August 2022, Biomedical chromatography : BMC,
Copied contents to your clipboard!